This announcement is a separate document:
北京市康达律师事务所关于昭衍新药调整2021年A股限制性股票激励计划授予权益数量及回购价格、终止实施2021年A股限制性股票激励计划及回购注销相关限制性股票的法律意见书
Legal opinion of Beijing Kangda Law Firm on Zhaoyan New Pharmaceutical\'s adjustment of the number of benefits and repurchase prices granted in the 2021 A-share restricted stock incentive plan, termination of implementation of the 2021 A-share restricted s
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.